Sun Pharma on Saturday announced its quarterly results ending December 2025.
Leading pharma company Sun Pharma on Saturday announced its quarterly results ending December 2025. In the information given to the exchange, the company said that the consolidated profit of the company increased by 16 percent on annual basis to Rs 3369 crore, which was Rs 2903 crore in the same quarter last year. During this period, the total income of the company increased by 13.5 percent to Rs 15,521 crore, whereas a year ago it was Rs 13,676 crore.
The company said EBITDA during the quarter jumped 23.4 per cent to Rs 4,949 crore from Rs 4,009 crore last year. However, EBITDA margin declined to 29.3 per cent from 31.9 per cent in the same quarter last year.
declaration of dividend
The company has declared dividend for its investors. The company has declared an interim dividend of Rs 11 per equity share (face value Rs 1) for the financial year 2025-26. The record date for the interim dividend has been fixed as 5 February 2026. The company said that this interim dividend will be paid to the eligible shareholders on or before 16 February 2026.
Read full article
Launched 12 new products
The company launched 12 new products during the quarter, while a total of 26 new products have been launched in the market since the beginning of the financial year (YTD). The company’s sales in the US stood at $477 million, which is about 27.5 percent of total consolidated sales. Currently, 57 NDAs (New Drug Applications) have been approved in the company’s portfolio, while 14 NDAs are awaiting approval from the US regulator US FDA.
Balanced growth in business segments
The company’s managing director Kirti Ganorkar said that the company’s results in this quarter show balanced growth in all business segments. Branded products played a strong role especially in India, emerging markets and global innovative medicine business.
He said that the company has further strengthened its new and innovative product portfolio. Unloxcyt has been launched in the US, while Ilumya has been introduced in India. These initiatives will provide better and differentiated modern treatment facilities to the patients and will further strengthen the innovation capability of the company.
Disclaimer: This article is for informational purposes only and should not be construed as investment advice in any way. ET NOW Swadesh recommends its readers and viewers to consult their financial advisors before taking any money-related decisions.
related news
end of article
